Acrivon Therapeutics to present Phase 2b study data on ACR-368 for endometrial cancer at ESGO Congress by Dr. Konstantinopoulos.
Renowned expert Dr. Panagiotis Konstantinopoulos from Dana-Farber Cancer Institute will present recent interim clinical findings from a Phase 2b study of ACR-368 in patients with endometrial cancer. The study is focused on obtaining registration.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments